Friday, May 23, 2014

ATTENTION IPF PATIENTS: Conference Call re: Pirfenidone


email header

Join an Important Coalition for Pulmonary Fibrosis Conference Call  
Tuesday May 27, 11 A.M. Eastern

Learn About Data on Three Important Drug Trial Outcomes from
Expert Andy Tager, M.D.

Dr. Tager will discuss data from from the InterMune, Boehringer Ingelheim and NIH Trials

Over the last few days, medical experts including researchers and physicians have been discussing the positive data reported by two drug trials in idiopathic pulmonary fibrosis (IPF) and negative results of a third, and discussing the long term meaning of the data at the American Thoracic Society (ATS) meeting in San Diego.  On Tuesday, patients will have an opportunity to learn about the data and ask their own questions.

The Coalition for Pulmonary Fibrosis (CPF) is hosting a conference call for patients and families affected by IPF.  Andrew Tager, M.D., an expert in IPF from Massachusetts General Hospital in Boston, MA, will be discussing the data reported on all three trials at the ATS conference.

The CPF represents thousands of patients suffering from the disease in the US that claims as many lives each year as breast cancer yet has limited awareness and recognition.

Who should join the call?  Pulmonary Fibrosis Patients, Family Members and Caregivers

What are the trials?  Boehringer Ingelheim’s Nintedanib, InterMune’s Pirfenidone and the National Institutes of Health’s PANTHER trial of N-acetylcysteine (NAC)

How to call in? Dial in number:  1-866-551-6201, login 303-521-4080.

When?  Tuesday, May 27, 11 a.m. Eastern, 10 a.m. Central, 8 a.m. Pacific

Why call?  To gain understand the meaning of the results of the drug trials and to ask questions

The call will be recorded and will be made available later in the day for those who miss the live call.  http://www.coalitionforpf.org/category/news-events/pf-news/

About Pulmonary Fibrosis (PF)
Pulmonary Fibrosis (PF) is a lung disorder characterized by a progressive scarring – known as fibrosis — and deterioration of the lungs, which slowly robs its victims of their ability to breathe. Approximately 200,000 Americans suffer from PF, and there is currently no known cause or cure. An estimated 48,000 new cases are diagnosed each year. PF is difficult to diagnose and an estimated two-thirds of patients die within five years of diagnosis. Sometimes PF can be linked to a particular cause, such as certain environmental exposures, chemotherapy or radiation therapy, residual infection, or autoimmune diseases such as scleroderma or rheumatoid arthritis. However, in many instances, no known cause can be established. When this is the case, it is called idiopathic pulmonary fibrosis (IPF).

About the CPF
The CPF is a 501C(3) nonprofit organization, founded in 2001 to accelerate research efforts leading to a cure for pulmonary fibrosis (PF), while educating, supporting, and advocating for the community of patients, families, and medical professionals fighting this disease. The CPF funds promising research into new approaches to treat and cure PF; provides patients and families with comprehensive education materials, resources, and hope; serves as a voice for national advocacy of PF issues; and works to improve awareness of PF in the medical community as well as the general public. The CPF’s nonprofit partners include many of the most respected medical centers and healthcare organizations in the U.S. With more than 28,000 members nationwide, the CPF is the largest nonprofit organization in the U.S. dedicated to advocating for those with PF. For more information please visit www.coalitionforpf.org or call (888) 222-8541.
 
Coalition for Pulmonary Fibrosis
10866 W. Washington Blvd. #343
Culver City, CA 90232
(888) 222-8541
info@coalitionforpf.org

No comments: